GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Waters Corp (NYSE:WAT) » Definitions » Capex-to-Revenue

Waters (Waters) Capex-to-Revenue : 0.05 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Waters Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Waters's Capital Expenditure for the three months ended in Dec. 2023 was $-41.59 Mil. Its Revenue for the three months ended in Dec. 2023 was $819.47 Mil.

Hence, Waters's Capex-to-Revenue for the three months ended in Dec. 2023 was 0.05.


Waters Capex-to-Revenue Historical Data

The historical data trend for Waters's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waters Capex-to-Revenue Chart

Waters Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.07 0.06 0.06 0.05

Waters Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.05 0.06 0.05 0.05

Competitive Comparison of Waters's Capex-to-Revenue

For the Diagnostics & Research subindustry, Waters's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Waters's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Waters's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Waters's Capex-to-Revenue falls into.



Waters Capex-to-Revenue Calculation

Waters's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-160.632) / 2956.416
=0.05

Waters's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-41.588) / 819.474
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Waters  (NYSE:WAT) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Waters Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Waters's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Waters (Waters) Business Description

Traded in Other Exchanges
Address
34 Maple Street, Milford, MA, USA, 01757
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2022, Waters generated 59% from pharmaceutical customers, 31% from industrial clients, and 10% from academic/government institutions.
Executives
Christopher A Kuebler director 210 CARNEGIE CENTER, PRINCETON NJ 08540
Richard H Fearon director 1239 GERBING ROAD, AMELIA ISLAND FL 32034
Edward Conard director
Daniel J. Brennan director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Mark P Vergnano director 1007 MARKET STREET, WILMINGTON DE 19898
Gary E Hendrickson director 1101 THIRD STREET SOUTH, MINNEAPOLIS MN 55415
John M Ballbach director
Linda Baddour director PRA INTERNATIONAL, 12120 SUNSET HILLS ROAD, SUITE 600, RESTON VA 20190
Michael J Berendt director
Thomas P Salice director
Wei Jiang director 34 MAPLE STREET, MILFORD MA 01757
Amol Chaubal officer: SVP and Chief Financial Office 113 HARTWELL AVE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421
Jianqing Bennett officer: SVP TA Instruments Division 34 MAPLE STREET, MILFORD MA 01757
Joann A Reed director C/O AMERICAN TOWER CORP, 116 HUNTINGTON AVENUE, BOSTON MA 02116
Belinda Hyde officer: SVP, Global Human Resources 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277

Waters (Waters) Headlines

From GuruFocus

Waters Corp at Jefferies Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Waters Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Waters Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Waters Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 Waters Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Waters Corp at Jefferies Healthcare Conference Transcript

By GuruFocus Research 01-23-2024